The Weekly Recap 4/18/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward
Received FDA Breakthrough Device Designation for its vCLAS™ Cryoablation System, a novel therapy for recurrent, drug-refractory, sustained monomorphic ventricular tachycardia. The designation validates Adagio’s proprietary ULTC technology and supports priority FDA review as the company advances its pivotal FULCRUM-VT study toward pre-market approval. This blog is originally Published here: https://shorturl.at/N3ECV
Synes godt om
Kommentar
Del
